Human After All

Cued by the Mary Anne Liebert journal Human Gene Therapy, serial entrepeuneur and investor Nessan Bermingham, PhD, examines the state of human gene therapy, its future, and the technical, financial, and regulatory obstacles.

Nessan has founded multiple companies in the Life Sciences space, most notably, Intellia Therapeutics. Currently, Nessan is an Operating Partner at Khosla Ventures. He focuses on companies with an emphasis on nucleic acid editing, novel delivery systems, gene & cell therapy, novel target identification and data analytics for drug discovery and development. Nessan is trained as a scientist. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine.

Hosted on Acast. See acast.com/privacy for more information.